“CytoDyn's lead asset leronlimab is set to be a

“CytoDyn's lead asset leronlimab is set to be a major player in the CCR5 inhibitors/antagonist market. The company has a market capitalization of $1.38 billion on a stock price of $2.42, which is in the lower quadrant of the 52-week range from $0.26 to $10.01. Over 86% of the 571 million outstanding shares are held by the public, while institutions, corporations and insiders hold 4%, 3.7% and 5.68% shares respectively. CytoDyn has a debt of $32.4 million, and cash burn in the TTM has been $87.6 million, whereas cash balance is very low at $18.20 million.”